Go back

EMA responds to ombudsman

The European Medicines Agency is still revising its privacy policy around clinical trials, following a nudge from the European Ombudsman over data protection concerns.

In a statement released on 12 November, the EMA said that it is continuing to implement its data publication policy, which is meant to improve clinical trial transparency in the EU. This is a slow process, the agency said, as it has to continuously discuss the definition of commercially confidential information since there is no agreed or binding definition for this term.

According to the agency, all the clinical trials reports released so far have been carefully examined in order to erase any data that could be considered confidential for both companies and people.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.